Akebia holder plans sale of 69772 shares

An unnamed holder of Akebia Therapeutics, Inc. common stock has filed a notice to sell 69772 shares under Rule 144.

Rhea-AI Filing Summary

An unnamed holder of Akebia Therapeutics, Inc. common stock has filed a notice to sell 69772 shares under Rule 144. The planned sale, with an aggregate market value of 97297.00, is to be executed through Morgan Stanley Smith Barney LLC on the Nasdaq around 02/02/2026. The securities are restricted stock originally acquired from Akebia on 01/31/2026, and the filing notes that total common shares outstanding are 265365993.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for Akebia Therapeutics (AKBA) in this notice?

The notice discloses a planned sale of 69772 shares of Akebia Therapeutics common stock. These are restricted shares, and the sale is being registered under Rule 144, allowing the holder to resell them subject to the rule’s conditions.

What is the aggregate market value of the Akebia (AKBA) shares to be sold?

The filing states an aggregate market value of 97297.00 for the 69772 Akebia Therapeutics common shares to be sold. This figure reflects the total market value of the planned Rule 144 sale as reported in the securities information table.

Which broker will handle the planned Akebia (AKBA) Rule 144 share sale?

The planned sale of 69772 Akebia Therapeutics common shares will be handled by Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 38th Floor, New York, NY 10004, as disclosed in the broker information section.

On which exchange and approximate date will the Akebia (AKBA) shares be sold?

The notice indicates the Nasdaq as the securities exchange for the sale, with an approximate sale date of 02/02/2026. This timing and venue apply to the planned Rule 144 sale of the 69772 common shares.

How many Akebia (AKBA) common shares are outstanding in this filing?

The securities information table lists 265365993 Akebia Therapeutics common shares outstanding. This number provides context for the issuer’s total equity base relative to the 69772 shares covered by the planned Rule 144 sale.

When and how were the Akebia (AKBA) shares to be sold originally acquired?

The 69772 Akebia Therapeutics shares to be sold were acquired as Restricted Stock on 01/31/2026 from Akebia Therapeutics, Inc. itself. The table lists a payment date of 02/02/2026 with the nature of payment described as “n/a.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:52 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002107264
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Akebia Therapeutics, Inc.
SEC File Number	001-36352
Address of Issuer	245 FIRST STREET CAMBRIDGE MASSACHUSETTS 02142
Phone	617-871-2098
Name of Person for Whose Account the Securities are To Be Sold	Rucci Carolyn M.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	69772	97297.00	265365993	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock	Akebia Therapeutics, Inc.			69772	02/02/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carolyn M. Rucci
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)